BPH: Costs And Treatment Outcomes

The document reviewed the costs and treatment outcomes for benign prostatic hyperplasia (BPH). It discussed various treatments, including pharmacotherapy with alpha1-selective adrenergic receptor (a1-AR) antagonists and 5-alpha-reductase inhibitors (5-aRIs), as well as invasive and minimally invasive interventions. Pharmacotherapy was the primary treatment for lower urinary tract symptoms (LUTS) caused by BPH, with a1-AR antagonists being more cost-effective than 5-aRIs and comparable in cost to surgical options. Tamsulosin, a subtype-selective a1-AR antagonist, was highlighted for its cost-effectiveness. The review noted a lack of comprehensive cost-effectiveness studies, particularly those considering adverse events, and suggested that further analyses could aid in selecting appropriate therapies for BPH patients.